A Clinical study regarding the changing rate of the bone strength of patients with hormone-sensitive breast cancer under the postoperative endocrine therapy

A Clinical study regarding the changing rate of the bone strength of patients with hormone-sensitive breast cancer under the postoperative endocrine therapy - The analysis of the bone strength under the postoperative endocrine therapy of breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033558

Enrollment

150

Registered

2018-09-01

Start date

2019-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

measure the distal end of radius by LD-100

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with stage 1-3A hormone-sensitive breast cancer and start the postoperative endocrine therapy within the period of this study 2) Estrogen receptor or progesterone receptor positive patients on immunohistochemical staining 3) Those from whom written informed consent regarding this study participation was obtained

Exclusion criteria

Exclusion criteria: 1)those can not attend University Hospital, Kyoto Prefectural University of Medicine 2)those are considered to be ineligible by the chief investigator

Design outcomes

Primary

Measure	Time frame
Changing rate for 12 months after starting the postoperative endocrine therapy in following four items derived by an ultrasonic bone measurement system, LD-100 Thickness of distal end of radius Thickness of cortical bone of radius Bone mineral density(BMD) of cancellous bone of radius Elasticity of cancellous bone of radius	—

Secondary

Measure	Time frame
1) Changing rate in the BMD for the lumbar vertebrae (L1-L4) on DXA 2) Changes in bone metabolism marker and the other date of blood 3) Relation between the bone strength and the activity, BMI and the clinical data 4) Appearance of morbid fracture within the period of this study 5) Efficacy of irisin, plasmalogen and etc as a biomarker and the relation between them and the activity, BMI and the clinical data 6) Stratified analysis of 1)-5)	—

Measure

Time frame

1) Changing rate in the BMD for the lumbar vertebrae (L1-L4) on DXA 2) Changes in bone metabolism marker and the other date of blood 3) Relation between the bone strength and the activity, BMI and the clinical data 4) Appearance of morbid fracture within the period of this study 5) Efficacy of irisin, plasmalogen and etc as a biomarker and the relation between them and the activity, BMI and the clinical data 6) Stratified analysis of 1)-5)

—

Countries

Japan

Contacts

Public ContactSatomi Tomida

Kyoto Prefectural Univercity of Medicine Department of Endocrine and Breast Surgery

satomida@koto.kpu-m.ac.jp0752515534

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026